1445592-11-9

Upstream product

• 1445592-10-8 (1R,2R)-2-(tert-butoxycarbonyl)-4-methoxycyclopentanecarboxylic acid 
• 1445592-09-5 (1R,2R)-1-tert-butyl 2-methyl 4-methoxycyclopentane-1,2-dicarboxylate 
• 1445592-08-4 (1R,2R)-1-tert-butyl 2-methyl 4-hydroxycyclopentane-1,2-dicarboxylate 
• 1445593-42-9 (1R,2R)-1-tert-butyl 2-methyl 4-oxocyclopentane-1,2-dicarboxylate 

Downstream Products

• 1445592-12-0 (1R,2R)-2-(5-(4-bromophenyl)-1H-imidazol-2-yl)-4-methoxycyclopentanecarboxylic acid 
• 1445590-87-3 ((1R,2R)-2-(5-(4-bromophenyl)-1H-imidazol-2-yl)-4-methoxycyclopentyl)((R)-3-methylmorpholino)methanone 

Relevant academic research and scientific papers

NOVEL HEPATITIS C VIRUS INHIBITORS

The invention provides compounds of formula (I): wherein Rings A and A' are independently 5-membered optionally substituted aromatic heterocycles; Q is C(=O)NR1R1' or formula U is C(R4)2, O, S, S(=O)2, C(R4)2C(R4)2, CH2O, OCH2, CH2S, SCH2, CH2S(=O)2, S(=O)CH2 or C=C(Ru )2; X is CH2, CHR12, CR12R12, O, S, S(=O)2 or NRx; m is 0, 1, 2 or 3; n is 0, 1, 2 or 3; the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.